Rankings
▼
Calendar
LGND FY 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$242M
+47.7% YoY
Gross Profit
$179M
74.3% margin
Operating Income
$104M
43.0% margin
Net Income
$57M
23.7% margin
EPS (Diluted)
$3.34
Cash Flow
Operating Cash Flow
$79M
Free Cash Flow
$70M
Stock-Based Comp.
$39M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$476M
Stockholders' Equity
$821M
Cash & Equivalents
$20M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$242M
$164M
+47.7%
Gross Profit
$179M
$133M
+34.7%
Operating Income
$104M
$38M
+176.9%
Net Income
$57M
-$3M
+2014.2%
← Q4 2020
All Quarters
Q1 2021 →